Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: a meta-analysis of randomized clinical trials

• Main Authors: Yuqian Wang (Author), Sheng Li (Author), Juan Bai (Author), Xiaoxuan Cai (Author), Shunli Tang (Author), Peiyi Lin (Author), Qingmiao Sun (Author), Jianjun Qiao (Author), Hong Fang (Author)
• Formato: Libro
• Publicado: SAGE Publishing, 2023-04-01T00:00:00Z.
• Subjects: article
• Acceso en liña: Connect to this object online.

Background: Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits both interleukin (IL)-17A and IL-17F, and is a promising drug for patients with moderate-to-severe plaque psoriasis. Objectives: This study aimed to assess the efficacy and safety of bimekizumab in treating patients with...